|
Variables
| |
N
|
6 M cumulative incidence of G2RP (%)
|
p value
|
6 M cumulative incidence of discontinuation of Durvalumab due to G2RP (%)
|
p value
| |
|---|
|
Gender
|
Male
|
37
|
48.7
|
0.038
|
21.6
|
0.03
| |
| |
Female
|
19
|
18.6
| |
0.0
| | |
|
Pulmonary Fibrosis Score
|
≥ 2
|
10
|
90.0
|
< 0.001
|
60.0
|
< 0.001
| |
| |
0–1
|
46
|
28.3
| |
4.3
| | |
|
Smoking history
|
Present
|
45
|
46.5
|
0.031
|
17.8
|
0.14
| |
| |
Never
|
11
|
9.0
| |
0.0
| | |
|
Lung V40
|
≥ 10%
|
30
|
57.3
|
0.011
|
20.0
|
0.21
| |
| |
< 10%
|
26
|
16.7
| |
7.7
| | |
|
Initial PTV
|
≥ 398 ml
|
24
|
58.3
|
0.024
|
25.0
|
0.048
| |
| |
< 398 ml
|
32
|
23.8
| |
6.3
| | |
|
Multivariate analysis
|
|---|
|
Variables
| |
HR
|
95% CI
|
p value
|
HR
|
95% CI
|
p value
|
|---|
|
Pulmonary Fibrosis Score
|
≥ 2
|
7.83
|
3.38–18.13
|
< 0.001
|
5.89
|
1.53–22.68
|
< 0.001
|
|
Lung V40
|
≥ 10%
|
3.17
|
1.09–9.19
|
0.034
| | | |
|
Initial
PTV
| | | | |
2.62
|
0.71–9.71
|
0.15
|
- Lung V40 percentage of the lung volume exceeding x Gy, Lung Vs5 volume of the lung received
less than 5 Gy, HR hazard ratio, PTV planning target volume
